Longer-Lasting Botox Rival Nears US Approval

Reloxin's makers claim it lasts longer
By Ambreen Ali,  Newser User
Posted Apr 2, 2009 8:25 AM CDT

(Newser) – After a 7-year run as the only show in town, Botox could soon face some competition. Awaiting FDA approval, Reloxin—the US version of a French product called Dysport—is being marketed as a quicker and longer-lasting treatment for botulinum toxin fans. But doctors themselves are confused about what differences, if any, exist between the wrinkle-smoothers, the New York Times reports.

Some docs use the drugs for different wrinkles, but see little disparity. Others purport that, with a practiced hand, they need less of Dysport to produce the same results as Botox. With each dose at more than $250, that could be a hefty savings. But Dysport novices, as many US doctors will be, may fumble until they figure out the proper dosages. (Read more Botox stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.